News from janssen therapeutics A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 05, 2014, 16:48 ET
OLYSIO(R) (simeprevir) Logo

OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection

Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO®...

Nov 25, 2013, 05:00 ET

VIDEO NOW AVAILABLE: OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved...

Nov 22, 2013, 20:25 ET

OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C

 Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved...

Jul 16, 2013, 08:30 ET

Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students

 Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced today the recipient of the second scholarship the company is...

May 30, 2013, 10:00 ET

Survey of Participants from Landmark GRACE Trial Provides Patients' Perspectives from an HIV Clinical Study

 A survey of a segment of clinical trial participants from the GRACE (Gender, Race And Clinical Experience) trial, the largest-ever study of...

Apr 24, 2013, 08:06 ET

Janssen Therapeutics LINCC™ Program Continues its Commitment to Underserved Populations with Charitable Contributions to 16 HIV/AIDS Organizations Across the U.S.

 Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from...

Dec 31, 2012, 09:00 ET

FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis

Janssen Therapeutics, Division of Janssen Products, LP, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated...

Dec 10, 2012, 16:01 ET

FDA Approves Prescribing Information Update for EDURANT® (rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients

 Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a...

Nov 09, 2012, 17:01 ET
PREZISTA(R) (darunavir) 800mg tablet.  (PRNewsFoto/Janssen Therapeutics)

FDA Approves New 800mg PREZISTA® (darunavir) Tablet

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved a new 800mg...

Jul 23, 2012, 08:30 ET

Award-Winning Documentary, The Other City, Returns to Washington, D.C. for AIDS 2012

Women, youth and healthcare disparities are among the HIV community topics that will be discussed at screenings of the documentary film The Other...

May 29, 2012, 09:00 ET

FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet

 Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has issued a Complete...

Apr 24, 2012, 09:24 ET

Watching, Reading and Listening: A New Way to Interact with Patient Information

 It lies within the compact folded rectangle that accompanies prescription medicines. In black and white on paper, it follows prescription...

Apr 12, 2012, 09:00 ET

Janssen Therapeutics Establishes Point Scholarship for LGBT Students

Janssen Therapeutics, Division of Janssen Products, LP, is supporting education for lesbian, gay, bisexual and transgender (LGBT) students through...

Mar 27, 2012, 08:00 ET

FDA Approves INTELENCE® (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1, Following Priority Review

 Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved...

Jan 05, 2012, 08:00 ET

Janssen Therapeutics Announces Latest Recipients of LINCC™ Funding Initiative

 Janssen Therapeutics, Division of Janssen Products, LP, today announced the funding recipients of the Linking In-Need Communities to Care...

Oct 21, 2011, 09:21 ET

FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label...

Sep 12, 2011, 09:00 ET

New Video Series Explores How People Living With HIV Have Overcome Emotional Barriers to Help Newly Diagnosed in Their Own Journeys

Chad says his HIV diagnosis in 2009 was the last in a series of life events that left him without hope. He remembers feeling as though he had lost...

Aug 01, 2011, 09:00 ET

Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds

Social stigma is the largest barrier to routine HIV testing by African-American frontline care physicians, according to a survey commissioned...

Jul 20, 2011, 09:03 ET

Janssen Therapeutics Teams Up With Celebrity Designer David Bromstad to Encourage HIV Testing

In an effort to elevate public awareness about the importance of HIV testing, Janssen Therapeutics, Division of Janssen Products LP, is teaming up...

Jul 19, 2011, 10:30 ET

EDURANT™ 96-Week Phase 3 Safety and Efficacy Data Presented at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO...